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Abstract All melanoma patients must be confirmed his-
tologically and resected according to Breslow. Sentinel
node biopsy must be done when tumor is over 1 mm or if
less with high-risk factors. Adjuvant therapy with inter-
feron must be offered for patients with high-risk melanoma
and in selected cases radiotherapy can be added. Metastatic
melanoma treatment is guided by mutational BRAF status.
BRAF wild type patients must receive anti-PD1 therapy
and BRAF mutated patients BRAF/MEK inhibitors or anti-
PD1 therapy. Up to 10 years follow up is recommended for
melanoma patients with dermatologic examinations and
physical exams.
Keywords Melanoma  Metastatic  Adjuvant 
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Methodology
As most of the knowledge on the treatment for this disease
has come in the last 5 years and from phase III clinical
trials for the development of this guideline, the authors
have reviewed all phase III trials regarding the main
aspects of this guideline and also the main guidelines on
this disease. Recommendation and evidence have been
graded according to the guidelines development recom-
mendations [1].
Surgical management of melanoma
When a confident clinical diagnosis of melanoma is made
excision biopsy should be performed. Excision biopsy must
have 2 mm (no larger, in order to not alter the lymphatic
drainage) of lateral surgical margins and deep margins in
the subcutis (Grade recommendation A; Level of Evidence
1a).
Regarding the surgical margins for melanoma in situ or
lentigo maligna complete excision should be made. There
are no randomized controlled trials about margins. A sur-
gical margin of 5–10 mm has shown low recurrences rates
(Grade recommendation A; Level of Evidence 2c). When
melanoma diagnostic is confirmed, the excision should be
performed with deep margins extending to the fascia
(Grade recommendation B; Level of Evidence 2b). Surgical
margins according to the Breslow thickness has been tested
in seven randomized trials (Grade recommendation A;
Level of Evidence 1a). Present data show surgical margins
of 1 cm for melanomas up to 1 mm Breslow. For 1–2 mm
of Breslow, margins could be of 1–2 cm (there have been
studies comparing 1–3 and 2–5 cm). Above 2 mm of
Breslow, 2 cm is recommended. A randomized study
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demonstrated that 1 cm of margin increased the locore-
gional recurrence and also risk of melanoma specific death
over 3 cm of margin (relative rate of melanoma death was
estimated to be 24 % higher in the 1 cm group than the
3 cm group on univariate analysis [hazard ratio (HR) 1.24;
95 % confidence interval (CI) 1.00–1.52; p = 0.05] [2].
Studies comparing 2 vs 4 cm did not reveal any benefit for
wider margins in melanomas of more than 2 mm of
Breslow. Only limited data are available for melanomas of
more than 4 mm of thickness. A surgical margin of more
than 3 cm is not beneficial.
Some patients are considered for Sentinel node biopsy.
In melanomas of more than 1 mm of Breslow a sentinel
node biopsy must be performed (Grade recommendation A;
Level of Evidence 1a). In patients with melanomas of
0.75–1 mm of Breslow and any risk factor as ulceration,
less than 40 years old, Clark level IV, regression or
increased mitotic rate, a sentinel node biopsy must be
considered as some studies have demonstrated sentinel
node metastases up to 20 % of cases [3] (Grade recom-
mendation B; Level of Evidence 1a). Complete lymph node
dissection consists of anatomically thorough dissection of
the involved nodal basin. It must be performed if sentinel
node is positive or there are clinically positive nodes
(stages IIB or IIIC). (Grade recommendation A; Level of
Evidence 2a).
In case of metastatic disease, surgical therapy of
metastases may be indicated. Data from retrospective
studies demonstrated survival rates of 20–30 % at 5 years
after surgical removal of single metastases (Grade rec-
ommendation B; Level of Evidence 2b).
Adjuvant therapy
Despite surgical treatment, an important part of the patients
may relapse. Some of the most important prognostic factors
for relapse are the tumoral thickness, the mitotic rate, the
presence of ulceration, and lymph node involvement.
Depending on its presence or absence, disease can be
divided into:
– Low-risk disease: stages I and IIA (T1–3 without
ulceration and T1–2 with ulceration). There is no
evidence of efficacy with adjuvant treatment in this
context.
– High-risk disease: stages IIB-C (T4 or with ulceration)
and stage III (N positive).
High-risk patients are considered candidates for adju-
vant treatment. The first drug approved in the high-risk
disease context was Interferon alpha (IFNa), based on the
results of the ECOG 1684 trial, where the high-dose
scheme (induction treatment with IFNa 20 MU/m2
iv 9 5 days/week 9 4 weeks, followed by maintenance
treatment with IFNa 10 MU/m2 sc 9 3 days/week 9 11
months) demonstrated a significant benefit in relapse-free
survival versus observation [4]. Although initially this
benefit extended to overall survival, a follow-up superior to
12 years showed no significant differences [5]. After that,
many studies have evaluated the efficacy and the toxicity
profile of this drug relative to other agents or different
schemes and dosage.
Alternative schemes with low-dose IFNa for 18 months
showed a significant improvement in RFS for stages II, but
not significant in overall survival [6]. However, evaluated
in the global context of high-risk population (stages II and
III), not only showed its inferiority versus the high-dose
scheme in relapse free survival, but also its inferiority with
the observational arm [7]. The poor results with low-dose
schemes could not be improved by the addition of initial
induction schemes neither with longer treatments.
With all of these conflicting results about benefit in OS,
recently several meta-analyses have tried to answer this
question. Whereas one of them confirmed the significant
improvement in RFS, but not for OS [8], two other meta-
analyses have demonstrated a significant benefit in OS [9,
10]. Nevertheless, none of them have been able to respond
the answer about the optimal IFNa treatment scheme and
which subgroup of patients will be the best candidates to
receive it.
Given these results, high-risk melanoma patients should
receive interferon adjuvant therapy (Grade recommenda-
tion A; Level of Evidence 1a).
It is expected a change in the therapeutic scene in next
years with the publication of the results of trials evaluating
new immunotherapy agents and BRAF/MEK inhibitors.
Radiotherapy
Adjuvant radiotherapy is rarely necessary for excised local
melanoma and should be considered in case of inadequate
resection margins of lentigo maligno, desmoplastic neu-
rotropic melanoma, which tends to be locally aggressive o
R1 resections of melanoma metastases when surgery is not
adequate (Grade of recommendation B; level of evidence
2b).
Adjuvant radiotherapy may be considered for select
patients with clinically positive nodes and features pre-
dicting a high risk of nodal basin relapse. A prospective
randomized trial with 250 non-metastatic patients and
radiotherapy (48 Gy) versus observation did not demon-
strate benefit in overall survival in the patients treated but it
demonstrated improvement in tumor control at lymph node
region [11]. Adjuvant radiotherapy is recommended when
there are three affected lymph nodes, or there is capsule
penetration or there is a lymph node metastases greater
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than 3 cm (Grade of recommendation C; level of evidence
1b). In addition, postoperative radiotherapy should be used
after resection of a lymphatic recurrence (Grade of Rec-
ommendation C, level of evidence 2b).
Many different options are available to patients pre-
senting with stage III in-transit metastases. Treatment is
based on the size, location and number of lesions. Radio-
therapy can be an alternative when these lesions are
inoperable or others alternatives as isolated limb perfusion
is not a possibility (Grade of recommendation C; level of
evidence 4).
Locoregional metastases
Patients with satellite and in-transit metastases should be
treated within the context of clinical studies if possible.
Surgical therapy of in-transit metastases shall be per-
formed when—with lack of indications of distant metas-
tasis—there is a possibility of macroscopic and
microscopic complete removal of the metastases (Grade of
recommendation B, level of evidence 4).
In the presence of multiple, inoperable, locoregional
cutaneous metastases on an extremity, regional chemother-
apy as isolated limb perfusion comes into consideration
(Grade of recommendation B, level of evidence 4). Metas-
tases outside of the perfusion area may be treated by intra-
tumoral injection of interleukin-2 (Grade of
recommendation B, level of evidence 4). Other procedures
such as radiation therapy, electrochemotherapy, cryosur-
gery, or laser destructionmay also be applied for local tumor
control (Grade of recommendation C, level of evidence 4).
Fundamental superiority of one over the other has not been
proven and their use depends on individuals factors.
Treatment of metastatic disease
The presence of BRAF-V600 mutation is mandatory for the
use of BRAF and MEK inhibitors (Grade of recommen-
dation A, level of evidence 1a). Validated BRAF-V600E/K
test methods are tissue based and provide qualitative data
(positive or negative).
First line therapy in BRAF-mutant, advanced
(IIIC/IV) melanoma
Three phase III trials have demonstrated that the combi-
nation of a BRAF inhibitor and a MEK inhibitor is more
active than single agent BRAF inhibitor: COMBI-
D dabrafenib and trametinib vs dabrafenib [12]; COMBI-
V dabrafenib and trametinib vs vemurafenib [13]; and
COBRIM vemurafenib and cobimetinib vs vemurafenib
[14]. (Over two-thirds of patients achieve an objective
response, time to progression lies in the range of
10–11 months and median overall survival is around
25 months) (Grade of recommendation A, level of evidence
1a.) A third combination (encorafenib and binimetinib) has
shown activity in a phase Ib/II study and a phase III study
is ongoing (NCT01909453).
Single agent BRAF inhibitors vemurafenib or dabrafe-
nib must be considered (response rate 50 %, time to pro-
gression 6–8 months, median overall survival
16–18 months) if the combination with their companion
MEK inhibitor cannot be used [15, 16] (Grade of recom-
mendation A, level of evidence 1a). The MEK inhibitor
trametinib as single agents is more active that DTIC, but
less effective than BRAF inhibitors.
BRAF inhibitors are also active in patients with brain
metastases response rate 30–39 %, overall survival
8 months [17]. Concomitant use with radiotherapy is not
recommended due to the risk of increased toxicity (Grade
of recommendation A, level of evidence 2a). The combi-
nation of BRAF and MEK inhibitors is currently being
tested in this setting.
Anti-CTLA4 and anti-PD1 antibodies have not been
directly compared with targeted therapies in advanced
melanoma, but clinical trials have consistently demon-
strated that its activity is not affected by BRAF muta-
tional status [18] (Grade of recommendation A, level of
evidence 1a).
Ipilimumab induces a significantly lower response rate
than BRAF inhibitors, but approximately 20 % of patients
achieve long-term survival (Grade of recommendation A,
level of evidence 1b), and might be a reasonable option in
patients with good performance status, low tumour burden
and normal LDH level [18].
Nivolumab and pembrolizumab, as well as the combi-
nation of nivolumab and ipilimumab are active and have a
higher response rate 43 and 33 % , respectively [19–21]
(Grade of recommendation A, level of evidence 1a); how-
ever, long-term results and the optimal duration of therapy
with these agents are not yet known.
Chemotherapy should only be considered as first line if
the more active options are not available or contraindicated
(Grade of recommendation A, level of evidence 1a).
Second line therapy in BRAF-mutant advanced
melanoma
The activity of BRAF and MEK inhibitors after
immunotherapy has not been prospectively studied, but
seems to be similar to that obtained in first line (Grade of
recommendation A, level of evidence 2b).
Retrospective data about the efficacy of ipilimumab
after BRAF inhibitors vary among investigators (median
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overall survival 5–12 months), but this result has been
related to treatment adherence, poor performance status
and rapid clinical deterioration.
The anti-PD1 antibodies nivolumab and pembrolizumab
are superior to chemotherapy in term of response rate
(26–31 %) and time to progression (3.7–4.7 months) in
patients pretreated with ipilimumab or BRAF inhibitors
(Grade of recommendation A, level of evidence 1b).
Treatment of BRAF wild type, advanced (IIIC/IV)
melanoma
Several chemotherapeutic agents (dacarbazine, temozo-
lamide, fotemustine, carboplatin, cisplatin, and paclitaxel
among others) have been tested in randomized clinical trials
with similar response rates (5–12 %) and suvival (\5 %)
results (Grade of recommendation A, level of evidence 1a).
The results of two randomized phase III studies have led
to the approval of Ipilimumab (3 mg/kg) for the treatment
of metastatic melanoma in first and second-line setting, due
to a significant improvement in median overall survival
(10 months) and long-term survival (20 %) (Grade of
recommendation A, level of evidence 1a). Response to
ipilimumab may delay 12 weeks or more after treatment
initiation and tumor response must be assessed after the
completion of four doses. Immune adverse events (skin,
gastrointestinal, liver, endocrine), usually resolve after
steroid treatment or hormonal replacement [22, 23].
Nivolumab and pembrolizumab [19, 21], as well as




All melanoma must be biopsied A 1a
Surgical margins should be Breslow adapted A 1a
Melanomas of more than 1 mm should undergo sentinel node biopsy A 1a
Melanomas of 0.75 mm should undergo sentinel node biopsy if there are risk factors B 1a
Lymph node resection should be performed if sentinel node is positive or clinically evident A 2a
Solitary metastases must be surgically removed B 2b
Adjuvant therapy
High risk melanoma patients should receive interferon adjuvant therapy A 1a
If surgical margins are affected adjuvant radiotherapy may be added B 2b
Adjuvant radiotherapy should be considered if more than 3 nodes are present, one is larger than
3 cm or capsule is broken
C 1b
Locoregional disease
Palliative radiotherapy can be used in transit metastases C 4
Surgery can be used for in transit metastases C 4
Isolated limb perfusion can be used for in transit metastases C 4
Metastatic disease
B-RAF determination should be done for all metastatic patients A 1a
Combined B-RAF/MEK inhibition should be offered for BRAF mutated patients A 1a
Single agent BRAF inhibitor is appropriate is there is contraindication for MEK inhibitor A 1a
BRAF inhibitors may be used in brain metastases A 2a
Immunotherapy results are not affected by BRAF status A 1a
Anti PD1 therapy is an alternative for BRAF mutated patients whose disease is not aggressively
progressing
A 1a
Chemotherapy is an option if no other therapy could be available A 1A
Patients treated with immunotherapy must be offered BRAF/MEK therapy as second line A 2b
Patients treated with BRAF/MEK inhibitors must be offered anti-PD1 therapy A 2a
Anti-PD1 therapy is the first option for BRAF wild type patients A 1a
Chemotherapy may be used as second line for BRAF wild type patients A 1a
KIT mutated melanomas may be offered KIT kinase inhibitors C 2b
Follow up
Ten year follow up must be offered B 1b
Lifelong skin examination is recommended B 3b
Self-examination is recommended B 3b
Physical examination is recommended A 2b
Lymph node sonogram is recommended if physical exam is not clear A 1A
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rate and survival than Ipilimumab (Grade of recommen-
dation A, level of evidence 1a) and have been approved by
FDA and EMA (only single agent nivolumab and pem-
brolizumab). The optimal duration of therapy and long-
term results with these agents is not yet known.
Results from case reports and a phase II study of KIT
inhibitor imatinib suggest that some patients with KIT
mutations (more common in acral lentiginous and mucosal
melanomas) may respond (10–20 %) to KIT kinase inhi-
bitor therapy (Grade of recommendation C, level of evi-
dence 2b), but these agents have not been approved for this
indication KIT as a therapeutic target in metastatic mela-
noma [24].
Follow up
The objective of follow-up is the early detection of recur-
rences and secondary melanomas. The optimal duration of
follow-up remains controversial (Table 1). Studies in stage
I–III showed that 47 % of recurrences occurred within the
first year after diagnosis and 32 and 80 % within the sec-
ond and third years, respectively, and thorough follow-up is
advocated for this time period. Late recurrences are well
documented but only 5 % of recurrences occur after
10 years. Thus, a 10-year follow-up appears to be reason-
able (Grade of recommendation B; level of evidence 1b).
Patients with a primary melanoma are at increased risk for
developing a second primary melanoma. Estimates of that
increased risk range from 8 to 10 %. Although the most
secondary melanomas occur within the first 2 years after
the primary diagnosis of melanoma may even occur more
than 30 years after, suggesting a need for life-long, regular
dermatologic examinations (Grade of recommendation B;
level of evidence 3b). Self-examinations by the patient are
an essential component of follow-up and can lead to early
recognition of recurrences of new melanomas. The patients
should receive instructions on self-examination to detect a
new melanoma or recognize a recurrence themselves
(Grade of recommendation B; level of evidence 3b).
Physical examinations in stage I–III disease have proven
to be the most effective procedure for early recurrence
detection [25] and shall be performed in all melanoma
patients during follow-up (Grade of recommendation A;
level of evidence 2b).
Routine blood testing to detect recurrence is not rec-
ommended (Grade of recommendation D; level of evidence
4). Early detection of locoregional lymph node metastases
is of particular significance. In a meta-analysis of 74 trials,
lymph node sonography proved to be the most sensitive
and most specific procedure for the detection of locore-
gional lymph node metastases and is the particular interest
in patients with and equivocal lymph node physical exam,
patients without sentinel lymph node biopsy (SLNB) or
patients with a positive SLNB who did not undergo com-
plete lymph node disection (Grade of recommendation A;
level of evidence 1a).
Overall, a general recommendation about imaging pro-
cedure is not possible, because there are no studies
assessing how the early detection of a recurrence could
have an impact in the overall survival with the new treat-
ments, as immunotherapy. In view of the current data, it is
possible that an early detection of recurrence could have an
impact in the response and evolution with the new treat-
ments. Individual follow-up exams may be conducted in a
risk-adapted fashion, trimonthly intervals in high risk of
recurrence and in patients with decreasing risk, follow-up
intervals may be extended from 6 to 12-months.
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